Literature DB >> 17525349

Orofacial pain in cancer: part II--clinical perspectives and management.

J B Epstein1, S Elad, E Eliav, R Jurevic, R Benoliel.   

Abstract

Cancer-associated pain is extremely common and is associated with significant physical and psychological suffering. Unfortunately, pain associated with cancer or its treatment is frequently under-treated, probably due to several factors, including phobia of opioids, under-reporting by patients, and under-diagnosis by healthcare workers. The most common etiology of cancer pain is local tumor invasion (primary or metastatic), involving inflammatory and neuropathic mechanisms; these have been reviewed in Part I. As malignant disease advances, pain usually becomes more frequent and more intense. Additional expressions of orofacial cancer pain include distant tumor effects, involving paraneoplastic mechanisms. Pain secondary to cancer therapy varies with the treatment modalities used: Chemo-radiotherapy protocols are typically associated with painful mucositis and neurotoxicity. Surgical therapies often result in nerve and tissue damage, leading, in the long term, to myofascial and neuropathic pain syndromes. In the present article, we review the clinical presentation of cancer-associated orofacial pain at various stages: initial diagnosis, during therapy (chemo-, radiotherapy, surgery), and in the post-therapy period. As a presenting symptom of orofacial cancer, pain is often of low intensity and diagnostically unreliable. Diagnosis, treatment, and prevention of pain in cancer require knowledge of the presenting characteristics, factors, and mechanisms involved.

Entities:  

Mesh:

Year:  2007        PMID: 17525349     DOI: 10.1177/154405910708600605

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  24 in total

1.  Nerve growth factor links oral cancer progression, pain, and cachexia.

Authors:  Yi Ye; Dongmin Dang; Jianan Zhang; Chi T Viet; David K Lam; John C Dolan; Jennifer L Gibbs; Brian L Schmidt
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

2.  Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?

Authors:  Giuseppe Colloca; Pasquale Colloca
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

Review 3.  A systematic review of orofacial pain in patients receiving cancer therapy.

Authors:  Joel B Epstein; Catherine Hong; Richard M Logan; Andrei Barasch; Sharon M Gordon; Loree Oberle-Edwards; Lorree Oberlee-Edwards; Deborah McGuire; Joel J Napenas; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-06-11       Impact factor: 3.603

4.  Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy.

Authors:  Ingrid Stenstrom Ling; Britt Larsson
Journal:  Support Care Cancer       Date:  2010-07-25       Impact factor: 3.603

Review 5.  Biologic mechanisms of oral cancer pain and implications for clinical therapy.

Authors:  C T Viet; B L Schmidt
Journal:  J Dent Res       Date:  2011-10-04       Impact factor: 6.116

6.  Pain is associated with an endophytic cancer growth pattern in patients with oral squamous cell carcinoma before treatment.

Authors:  Jun Sato; Yutaka Yamazaki; Akira Satoh; Ken-Ichi Notani; Yoshimasa Kitagawa
Journal:  Odontology       Date:  2010-02-16       Impact factor: 2.634

7.  Analgesia targeting IB4-positive neurons in cancer-induced mechanical hypersensitivity.

Authors:  Yi Ye; Dongmin Dang; Chi T Viet; John C Dolan; Brian L Schmidt
Journal:  J Pain       Date:  2012-04-05       Impact factor: 5.820

8.  Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy.

Authors:  Joel B Epstein; Diana J Wilkie; Dena J Fischer; Young-Ok Kim; Dana Villines
Journal:  Head Neck Oncol       Date:  2009-07-14

9.  Anxiety, depression, and pain: differences by primary cancer.

Authors:  Dena J Fischer; Dana Villines; Young Ok Kim; Joel B Epstein; Diana J Wilkie
Journal:  Support Care Cancer       Date:  2009-08-17       Impact factor: 3.603

10.  Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer.

Authors:  Jung Hye Kwon; David Hui; Gary Chisholm; Eduardo Bruera
Journal:  Oncologist       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.